Concentration-dependent inhibitory effect of irbesartan on renal uric acid transporters
Makiko Nakamura1, Naohiko Anzai, Promsuk Jutabha
1Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Abstract:
Hyperuricemia is currently recognized as a risk factor for cardiovascular diseases. It has been reported that the angiotensin II-receptor blocker (ARB) losartan decreases serum uric acid level. In this study, the effects of another ARB, irbesartan, on [(14)C]uric acid-transport activity of renal uric acid reabsorptive transporters URAT1 and URATv1 were examined with Xenopus oocytes expressing each transporter. The results showed that irbesartan (100-500 µM) inhibited the uptake of uric acid via both transporters. The inhibitory effects of irbesartan exceeded those of losartan and other ARBs, and the results suggest that irbesartan can reduce serum uric acid level.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Renal Drug Excretion: Tubular Secretion
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Drug Elimination by Renal Route: Tubular Secretion
Antihypertensive Drugs: Action of Diuretics
Drug Elimination by Renal Route: Tubular Reabsorption
![Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F61682.jpg&w=3840&q=50)
